Showing results (21-30 of 99) with videos related to
Sort By:
Pageof 10
Journal of Pharmaceutical Sciences|December 18, 2001
Limited phase I study of morphine-3-glucuronideR T Penson, S P Joel, S Clark, et al.British Journal of Cancer|October 1, 1994
Lack of effect of interferon alpha 2a upon fluorouracil pharmacokineticsM T Seymour, N Patel, A Johnston, et al.British Journal of Clinical Pharmacology|March 16, 2000
The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphineR Stuart-Harris, S P Joel, P McDonald, et al.Human Nutrition. Applied Nutrition|August 1, 1987
Oral protein and energy supplements in cancer patientsS A Parkinson, J Lewis, R Morris, et al.British Journal of Cancer|September 1, 1985
The effect of food and concurrent chemotherapy on the bioavailability of oral etoposideV J Harvey, M L Slevin, S P Joel, et al.Cancer Treatment Reports|June 1, 1985
High-dose etoposide in the treatment of relapsed primary brain tumorsG P Finn, T Bozek, R L Souhami, et al.Cancer Chemotherapy and Pharmacology|January 1, 1983
Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusionM L Slevin, E M Piall, G W Aherne, et al.Cancer Chemotherapy and Pharmacology|January 1, 1984
High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphomaA Rohatiner, M L Slevin, H S Dhaliwal, et al.Journal of Immunological Methods|August 30, 1992
Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditionsP W Thavasu, S Longhurst, S P Joel, et al.Cancer Chemotherapy and Pharmacology|January 1, 1986
The effect of dose on the bioavailability of oral etoposideV J Harvey, M L Slevin, S P Joel, et al.Pageof 10